Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Wion RK, Hill NL, Mogle J, Bhargava S, Berish D, Kolanowski A. Scoring of leisure activities for older adults according to cognitive, physical, and social components. Res Gerontol Nurs. 2020 Jan 1;13(1):13-20. doi: 10.3928/19404921-20191022-01
Park EM, Deal AM, Yopp JM, Edwards TP, Wilson DJ, Hanson LC, Rosenstein DL. End-of-life experiences of mothers with advanced cancer: perspectives of widowed fathers. BMJ Support Palliat Care. 2016 Dec;6(4):437-44. doi: 10.1136/bmjspcare-2015-000976
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603